3. The antibody, antigen-binding fragment or variant, of claim 1, wherein said variant comprises heavy and light chain CDRs having at least 98% sequence identity to the CDRs of said antibody.

4. The antibody, antigen-binding fragment or variant, of claim 1, wherein said variant comprises heavy and light chain CDRs having at least 99% sequence identity to the CDRs of said antibody.

5. The antibody, antigen-binding fragment or variant, of claim 1, which also binds IL-17A/IL-17F heterodimeric complex.

6. The antibody, antigen-binding fragment or variant, of claim 1, which is an IgG isotype.

7. The antibody, antigen-binding fragment or variant, of claim 6, which is an IgG1 or IgG4 isotype.

8. The antibody, antigen-binding fragment or variant, of claim 7, which is an IgG1 isotype.

9. The antibody, antigen-binding fragment or variant, of claim 7, which is an IgG4 isotype.

10. The antibody, antigen-binding fragment or variant, of claim 1, wherein the antibody comprises a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 85, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 86, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 87, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 110, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97 and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 111.

11. The antibody, antigen-binding fragment or variant, of claim 1, wherein the antibody comprises a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 85, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 94, a VH CDR3 region